A phase IV randomized, multicenter, open-label study to compare the safety, tolerability and efficacy of Trizivir (abacavir 300mg, lamivudine 150mg, and zidovudine 300mg) bid vs Combivir (lamivudine 150mg and zidovudine 300mg) bid plus atazanavir 400mg qd in antiretroviral naive HIV-1 infected subjects over 48 weeks.

Trial Profile

A phase IV randomized, multicenter, open-label study to compare the safety, tolerability and efficacy of Trizivir (abacavir 300mg, lamivudine 150mg, and zidovudine 300mg) bid vs Combivir (lamivudine 150mg and zidovudine 300mg) bid plus atazanavir 400mg qd in antiretroviral naive HIV-1 infected subjects over 48 weeks.

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 May 2017

At a glance

  • Drugs Atazanavir (Primary) ; Lamivudine/zidovudine (Primary) ; Lamivudine/zidovudine/abacavir (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms ACTION
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Oct 2008 Actual start date changed from May 2004 to Apr 2004 as reported by Clinicaltrials.gov
    • 17 Jul 2007 Status change from in progress to completed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top